Does Rallies show 13F holders for NUVL?

Yes. Rallies tracks hedge fund and 13F ownership data for NUVL, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NUVL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NUVL. It does not provide personalized investment advice.

NUVL (Nuvalent, Inc. Class A Common Stock) Stock Analysis - Hedge Fund Holdings

Nuvalent, Inc. Class A Common Stock (NUVL) is a publicly traded Healthcare sector company. As of May 21, 2026, NUVL trades at $102.11 with a market cap of $7.89B and a P/E ratio of -17.40. NUVL moved +1.30% today. Year to date, NUVL is +4.47%; over the trailing twelve months it is +34.84%. Its 52-week range spans $55.54 to $113.02. Analyst consensus is strong buy with an average price target of $140.85. Rallies surfaces NUVL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NUVL stock?

Hedge funds tracked by Rallies that own NUVL include Bridgewater Associates, Polen Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Nuvalent, Inc. Class A Common Stock.

NUVL Key Metrics

Key financial metrics for NUVL
Metric	Value
Price	$102.11
Market Cap	$7.89B
P/E Ratio	-17.40
EPS	$-5.85
Dividend Yield	0.00%
52-Week High	$113.02
52-Week Low	$55.54
Volume	536
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-425.38M
Gross Margin	0.00%

Top Hedge Funds Holding NUVL

Bridgewater Associates holds 15.02K shares of NUVL, changed -19.15% as of Mar 31, 2026.
Polen Capital holds 12.74K shares of NUVL, changed +100.41% as of Mar 31, 2026.
Farallon Capital holds 3.00K shares of NUVL, changed +0.00% as of Mar 31, 2026.

Latest NUVL News

Nuvalent drops as Q1 results and FDA program updates hit tape — May 7, 2026
Nuvalent climbs as Guardant diagnostic partnership and ASCO catalyst focus returns — May 4, 2026
Nuvalent slides as FDA zidesamtinib NDA review and AACR data spark profit-taking — Apr 26, 2026
Nuvalent slides 3% as profits are taken ahead of May 7 earnings — Apr 25, 2026
Nuvalent slides as biotech risk-off hits, after ASCO catalyst and April FDA filing — Apr 24, 2026

Recent NUVL Insider Trades

Miller Deborah Ann sold 4.42K (~$437.96K) on Apr 30, 2026.
Miller Deborah Ann sold 1.08K (~$107.73K) on Apr 30, 2026.
Noci Darlene sold 4.50K (~$447.07K) on Apr 29, 2026.

NUVL Analyst Consensus

14 analysts cover NUVL: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $140.85.

Common questions about NUVL

Who owns NUVL stock?: Hedge funds tracked by Rallies that own NUVL include Bridgewater Associates, Polen Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Nuvalent, Inc. Class A Common Stock.
Does Rallies show 13F holders for NUVL?: Yes. Rallies tracks hedge fund and 13F ownership data for NUVL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NUVL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NUVL. It does not provide personalized investment advice.